Trial Profile
Effects of Ipragliflozin on the Diurnal Profiles of Plasma Glucose and 3-hydroxybutyrate in Patients with Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2015
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 23 Jul 2015 New trial record
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.